[Use of high-dose olanzapine for treatment of acute relapse of schizophrenia in a patient with bad tolerance of typical neuroleptics. Case report].
OBJECTIVE
The purpose of the study was to assess the efficacy of high doses of olanzapine for treatment of the patient suffering from schizophrenia with predominance of positive symptoms. The blood levels of prolactin and glucose were monitored in order to determine the influence of high dose of olanzapine on these levels and to make a comparison between olanzapine and typical neuroleptics in this aspect.


METHODS
The patient suffering from schizophrenia with predominance of positive symptoms, poorly tolerating typical neuroleptics and with no positive result of a standard dose of olanzapine treatment, was treated with high doses of olanzapine. PANSS was used to assess severity of symptoms, to rate side effects. The authors used Webels modification of Simpson and Angus scale.


RESULTS
During the high dose olanzapine treatment a marked reduction of PANSS score was achieved. Also the reduction of score in Simpson and Angus scale was observed, high level of this score at the beginning was due to classical neuroleptic treatment. There was no increase in blood prolactin level (in comparison with the high earlier one after typical neuroleptic treatment), whilst glucose level was not elevated.


CONCLUSIONS
High dose olanzapine seems to be an effective and safe method of treatment of paranoid schizophrenia with predominance of positive symptoms in patients poorly tolerating typical neuroleptics.
Niedoborek
Arkadiusz
A
Kliniki Psychiatrii AM w Lublinie.
Wójcicka
Anna
A
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000008:administration & dosage*; D001786:Blood Glucose / Q000378:metabolism; D003863:Depression / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D000077152:Olanzapine; D011044:Poland; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D055502:Secondary Prevention; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D001786:Blood Glucose; D000077152:Olanzapine; D011388:Prolactin; D017367:Selective Serotonin Reuptake Inhibitors